What is the typical treatment for autoimmune hepatitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Autoimmune Hepatitis

The standard first-line treatment for autoimmune hepatitis is combination therapy with prednisone 30 mg/day (tapering to 10 mg/day over 4 weeks) plus azathioprine 1-2 mg/kg/day, continued for at least 2 years and for at least 12 months after complete normalization of liver enzymes and IgG levels. 1, 2, 3

Initial Treatment Regimen

Combination therapy is superior to monotherapy, producing significantly fewer corticosteroid-related side effects (10% versus 44%) while achieving remission in 80-90% of patients. 1, 3

Standard Dosing Schedule:

  • Week 1: Prednisone 30 mg/day + Azathioprine 50 mg/day (US) or 1-2 mg/kg/day (Europe) 1, 2
  • Week 2: Prednisone 20 mg/day + Azathioprine (same dose) 2
  • Weeks 3-4: Prednisone 15 mg/day + Azathioprine (same dose) 2
  • Maintenance: Prednisone 10 mg/day + Azathioprine (same dose) until treatment endpoint 1, 2

Important Timing Consideration:

The European Association for the Study of the Liver recommends starting prednisone first, then adding azathioprine after 2 weeks, particularly when bilirubin is below 6 mg/dL—this is safer in patients with severe hyperbilirubinemia. 2, 3

Alternative First-Line Options

Prednisone Monotherapy:

Use prednisone alone (starting at 60 mg daily, tapering to 20 mg maintenance) in specific situations: 3

  • Pre-existing cytopenia
  • Pregnancy
  • Thiopurine methyltransferase (TPMT) deficiency
  • Active malignancy

Check TPMT activity before starting azathioprine to exclude homozygote deficiency, especially in patients with pre-existing leucopenia. 2, 3

Budesonide-Based Therapy:

Budesonide 9 mg/day plus azathioprine may be used only in treatment-naive, non-cirrhotic patients with early-stage disease who face high risk of steroid side effects. 2, 3

Critical caveat: Budesonide should NOT be used in patients with cirrhosis or acute severe autoimmune hepatitis due to risk of systemic side effects and inadequate efficacy. 3

Treatment Goals and Monitoring

Complete normalization of BOTH serum aminotransferases AND IgG levels must be the treatment goal—persistent elevations predict relapse, ongoing histological activity, progression to cirrhosis, and poor outcomes. 2

Monitoring Schedule:

  • Initial response assessment: 4-8 weeks after treatment initiation 1, 2
  • Early improvement: Serum aminotransferase levels should improve within 2 weeks of starting therapy 1, 3
  • Monthly monitoring: Check serum aminotransferase levels monthly, as small decrements in prednisone dose can trigger marked increases 1
  • Time to normalization: Average duration is 19 months, with 66-91% achieving normal liver tests within 2 years 2

Biochemical remission achieved within 6 months is associated with lower frequency of progression to cirrhosis. 1

Pre-Treatment Withdrawal Assessment:

Liver biopsy assessment prior to termination of treatment is recommended to ensure full resolution—55% of patients with normal serum enzymes still show persistent interface hepatitis on biopsy. 3

Management of Acute Severe Autoimmune Hepatitis

For acute severe presentations, immediately administer high-dose intravenous corticosteroids (≥1 mg/kg) as early as possible. 2, 3

If no improvement occurs within 7 days, list for emergency liver transplantation. 2, 3

Treatment Failure and Second-Line Options

Definition and Initial Management:

For confirmed non-responders, increase to high-dose therapy: 2, 3

  • Prednisone 60 mg daily alone, OR
  • Prednisone 30 mg daily plus azathioprine 150 mg daily
  • Continue for at least 1 month

Second-Line Agents for Steroid-Refractory Cases:

Mycophenolate mofetil (MMF) is recommended as the first second-line agent, particularly for azathioprine intolerance: 3

  • Initial dose: 1 g daily
  • Maintenance: 1.5-2 g daily

Tacrolimus may be more effective for refractory disease not responding to standard therapy: 1, 3

  • Starting dose: 0.075 mg/kg daily

Cyclosporine has shown effectiveness in inducing and maintaining remission: 1, 3

  • Dose: 2-5 mg/kg daily
  • Particularly effective in pediatric patients 3

Long-Term Management and Relapse

Relapse occurs in 50-90% of patients within 12 months of stopping treatment, even after achieving complete biochemical and histological remission. 1, 2

Only 20-28% achieve sustained remission off therapy. 2

After Relapse:

  • Re-treat with combination prednisone and azathioprine therapy 1
  • Consider long-term maintenance with azathioprine 2 mg/kg/day 1, 2
  • For patients who have relapsed more than once, 87% remain in remission during long-term maintenance (median 67 months) 1

Prevention of Treatment Complications

All patients should receive: 1, 2

  • Calcium and vitamin D supplementation
  • DEXA scanning at 1-2 year intervals to monitor bone mineral density
  • Early vaccination against hepatitis A and B in susceptible patients

Timeline of Complications:

Severe complications (osteoporosis, vertebral compression, diabetes, cataracts, hypertension, psychosis) typically develop after 18 months of therapy at prednisone doses >10 mg daily. 1, 3

Cosmetic side effects occur in 80% of patients after 2 years of treatment. 3

Minimize cumulative steroid exposure to reduce the risk of these complications. 2

References

Guideline

Treatment of Autoimmune Hepatitis Type 2

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Autoimmune Hepatitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Autoimmune Hepatitis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.